Trial reportNature medicine2023
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Trial report in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 116 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Placebo After Complete Resection of Stage IIB/C Melanoma
Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
Who cites it
116 citing papers in PubMed, 9 syntheses or guidelines pooled it, 180 citations in OpenAlex.
- Sex, Timing, and Outcomes of Curative-Intent Immunotherapy: A Systematic Review and Meta-Analysis.JAMA network open · 2026Pooled it
- Cancer-related fatigue during treatment with neoadjuvant and/or adjuvant immune checkpoint inhibitors: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Pooled it
- Defining and modeling 'cure' in early-stage melanoma: perspectives from a systematic literature review.Frontiers in oncology · 2026Pooled it
- Adjuvant immune checkpoint inhibitors across solid tumors: a meta-analysis of phase II-III randomized trials.Frontiers in oncology · 2026Pooled it
- Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis.Journal for immunotherapy of cancer · 2025Pooled it
- Pooled it
- Assessing the clinical, humanistic, and economic impact of early cancer diagnosis: a systematic literature review.Frontiers in oncology · 2025Pooled it
- SEOM-GEM clinical guidelines for cutaneous melanoma (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Impact of adjuvant therapy on melanoma-specific survival in elderly patients with high-risk resected melanoma: a multicenter international retrospective study.Journal for immunotherapy of cancer · 2026Article
- Review
- Review
- [Data and clinical experience of patients undergoing sentinel lymph node biopsy between 2020 and 2025 at the National Institute of Oncology, Hungary].Magyar onkologia · 2026Article
- Linking early and late endpoints in adjuvant immunotherapy trials: an evaluation of multiple clinical outcomes.The oncologist · 2026Article
- Amelanotic subungual melanoma mimicking a glomus tumor: A diagnostic pitfall requiring thumb amputation.JAAD case reports · 2026Article
- Durable benefits, but no improvements in overall survival: what can we learn from CheckMate 238 after 9 years of follow-up?Translational cancer research · 2026Article
- Management of Advanced Solid Tumors Recurring After Adjuvant Immune Checkpoint Inhibitors: A Structured Narrative Review.Current oncology (Toronto, Ont.) · 2026Review
- Article
- Adjuvant Immunotherapy for High-Risk Stage II Melanoma: Real-World Utilization and Associated Overall Survival.Annals of surgical oncology · 2026Article
- Assessing the Impact on Health and Productivity Outcomes of Anti-PD-(L)1 Agents to Treat Early-Stage Cancers in Italy.Clinical drug investigation · 2026Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
21 authors at 18 institutions in 8 countries.
Funding
Abstract
Patients with resected stage IIB/C melanoma have high recurrence risk, similar to those with resected stage IIIA/B disease. The phase 3, double-blind CheckMate 76K trial assessed 790 patients with resected stage IIB/C melanoma randomized 2:1 (stratified by tumor category) to nivolumab 480 mg or placebo every 4 weeks for 12 months. The primary endpoint was investigator-assessed recurrence-free survival (RFS). Secondary endpoints included distant metastasis-free survival (DMFS) and safety. At 7.8 months of minimum follow-up, nivolumab significantly improved RFS versus placebo (hazard ratio (HR) = 0.42; 95% confidence interval (CI): 0.30-0.59; P < 0.0001), with 12-month RFS of 89.0% versus 79.4% and benefit observed across subgroups; DMFS was also improved (HR = 0.47; 95% CI: 0.30-0.72). Treatment-related grade 3/4 adverse events occurred in 10.3% (nivolumab) and 2.3% (placebo) of patients. One treatment-related death (0.2%) occurred with nivolumab. Nivolumab is an effective and generally well-tolerated adjuvant treatment in patients with resected stage IIB/C melanoma. ClinicalTrials.gov identifier: NCT04099251 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.